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Vancomycin-resistant Enterococcus faecalis (VREfs) is an important hospital-21 
adapted pathogen. We undertook whole genome sequencing of E. faecalis associated with 22 
bloodstream infection in the United Kingdom and Ireland (UK&I) over more than a decade 23 
to determine the population structure and genetic associations with hospital adaptation.  24 
Three lineages predominated in the population, two of which (L1 &L2) were nationally 25 
distributed and L3 was geographically restricted. Genome comparison with a global 26 
collection identified that L1 and L3 were also present in the United States but were  27 
genetically distinct. Over 90% of VREfs belonged to L1-3, with resistance acquired and lost 28 
multiple times in L1 and L2, but only once followed by clonal expansion in L3. Putative 29 
virulence and antibiotic resistance genes were over-represented in L1, L2 and L3 isolates 30 
combined, versus the remainder. Each of the 3 main lineages contained a mixture of 31 
vancomycin-resistant and –susceptible E. faecalis (VSEfs), which has important implications 32 
for infection control and antibiotic stewardship. 33 
  34 
Enterococci are the second and third most frequent cause of nosocomial infections in 35 
the United States (US) and Europe respectively,1,2 with Enterococcus faecalis the most 36 
commonly isolated species.2 Vancomycin is the first-line antimicrobial drug for enterococci 37 
with high-level resistance to ampicillin or for patients with penicillin allergy. Vancomycin 38 
resistance was first reported in 19883 and subsequently increased in prevalence. This rise was 39 
predominantly due to E. faecium, but E. faecalis accounted for 11% of VRE bacteremias in the 40 
UK&I between 2001-2013 (http://www.bsacsurv.org).  Based on multi-locus sequence typing 41 
(MLST)4, vancomycin resistance in E. faecalis has arisen in multiple genetic backgrounds,5,6 42 
and is associated with epidemic lineages7 Microbial genome sequencing provides the 43 
opportunity to gain a detailed understanding of the molecular basis for hospital adaptation. 44 
The first whole-genome sequence of E. faecalis was published in 2003.8 Subsequent genome 45 
studies have compared 18 E. faecalis strains, which demonstrated the contribution of mobile 46 
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genetic elements to the diversity of the species;9 and 25 clinical and 7 non-clinical isolates, 47 
which revealed that both were comparable in gene content.10 The ability to sequence large 48 
bacterial collections means that the molecular epidemiology and gene content of epidemic 49 
and sporadic lineages can now be systematically defined.  50 
We sequenced 168 E. faecalis isolates (58 VREfs, 110 VSEfs) from national (British 51 
Society for Antimicrobial Chemotherapy (BSAC) n=94), local (Cambridge University Hospitals 52 
NHS Foundation Trust (Addenbrooke’s Hospital and The Rosie Hospital) (CUH, n=60), and 53 
reference (National Collection of Type Cultures (NCTC) n=14) collections (see Supplementary 54 
Table 1). BSAC isolates originated from 21 UK&I hospitals between 2001 and 2011 (see 55 
Supplementary Fig. 1 for geographical and temporal distribution), and CUH isolates were 56 
collected between 2006 and 2012. All BSAC and CUH isolates were associated with 57 
bloodstream infection. NCTC isolates were from humans, livestock and food products and 58 
were predominantly isolated prior to 1951 (10/14 isolates).  59 
 Comparison of these genomes against the core genome of E. faecalis V583 identified 60 
124,194 single nucleotide polymorphisms (SNPs) over 2,886,189 nucleotides (Fig. 1). A 61 
striking feature of the phylogenetic tree based on these SNPs was that 53% of isolates 62 
clustered into three distinct lineages (termed L1, L2 & L3). L1 was represented in each year of 63 
the collection, while L2 was most frequently represented between 2001 and 2006 after which 64 
there were only two isolates identified that belonged to this lineage (Supplementary Fig. 1). 65 
This suggests clonal replacement, a phenomenon observed for other hospital-related 66 
pathogens such as methicillin-resistant Staphylococcus aureus.11 Annotation of lineage-67 
specific trees with geographical location demonstrated that L1 and L2 were nationally 68 
distributed (epidemic) clones, whilst L3 was only isolated in two locations (CUH and a hospital 69 
in the East Midlands referral network12) (Fig. 1).  L3 was the dominant lineage at CUH (17/60 70 
study isolates) and accounted for 3/13 isolates from a hospital in the East Midlands, the 71 
phylogenetic tree supporting a single introduction into this hospital followed by local 72 
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diversification. We also explored the phylogenetic origins of VREfs by including all available E. 73 
faecalis isolates from the NCTC collection. Eleven of 14 NCTC isolates clustered with recent 74 
clinical isolates (Fig. 1), including seven isolated prior to 1951, and two VREfs from 1986 (the 75 
first year that VREfs was recognised) that belonged to L1 or L2, which in the case of L2 may 76 
represent a founder of the circulating vancomycin-resistant E. faecalis lineage.  77 
To place our collection into a global context we compared these to the E. faecalis 78 
genomes of isolates from around the world. This was achieved by retrieving all of the E. 79 
faecalis genomes (n=353) held by the European Nucleotide Archive (ENA) as of 10/09/2015, 80 
and combining our data with 347 of these (excluding 6 based on data quality). The 81 
phylogenetic tree based on 1,293 genes conserved in 99% of these 515 isolates revealed that 82 
isolates contained within L1 and L3 that originated from the UK and United States were 83 
genetically distinct (Fig. 2). This indicates independent clonal expansion of dominant lineages 84 
with limited international dissemination. One explanation for this is that these lineages are 85 
hospital-associated with limited carriage beyond hospitals. Studies investigating community 86 
carriage of VRE in the US and UK have failed to identify VREfs.13,14 By contrast, global isolates 87 
from the non-dominant STs were closely related to UK isolates. 88 
To compare our findings with those of published studies based on MLST, we assigned 89 
STs to all 168 study isolates (see Supplementary Table 1). Isolates in L1 were assigned to ST6, 90 
ST384 and ST642 (CC2), and L2 isolates were ST28 and ST640 (CC87). Both CCs have been 91 
described as high-risk lineages based on their association with hospital-derived isolates in 92 
Europe.5–7 L3 isolates were ST103 (CC388), which has only been reported previously in 93 
relation to five clinical and two fecal isolates, all from the Americas.10  94 
 Comparison of the number of core genome SNPs for L1, L2 and L3 revealed lower 95 
genetic diversity for L3 (range 3-60 SNPs, median 33 SNPs), compared with L1 (range 2-375 96 
SNPs median 30 SNPs), and L2 (range 0-237 SNPs, median 139 SNPs). This led us to use 97 
Bayesian Evolutionary Analysis Sampling Trees (BEAST) to date these lineages.15 The last 98 
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common ancestor of L3 was estimated to be 1998 (95% highest posterior density (HPD) 99 
interval, 1980-2004) (Supplementary Fig. 2a), consistent with the earliest reported isolation 100 
of ST103 in the literature of 2002.10 The last common ancestor of L1 was predicted to be 1918 101 
(95% HPD interval, 1868-1960), with a clonal expansion in 1997 (95% HPD interval, 1992-102 
2000) (Supplementary Fig. 2b). The early estimate for the last common ancestor of L1 relied 103 
on just three outlying isolates, and so a second algorithm was used to detect and remove 104 
recombination events and the BEAST analysis repeated to rule out the role of undetected 105 
recombination. This predicted a last common ancestor in 1852 (95% HPD interval, 1811-106 
1956). It has been proposed previously that CC2 (L1) emerged recently, based on the lack of 107 
isolates identified prior to the 1980s.16 Our analysis indicates that this lineage may have been 108 
in existence since the mid 1850s to early 1900s, with a clonal expansion in the 1990s. BEAST 109 
analysis of L2 failed, probably because of a limited number of isolates with high genetic 110 
diversity and wide temporal spread. 111 
Establishing the rate of mutation in the core genome provides a molecular clock that 112 
contextualises analyses of bacterial genomes during putative outbreak investigations,17–19 but 113 
has not been defined previously for E. faecalis. The rate of evolution was estimated to be 114 
8.18x10-7 SNPs/site/year (approximately 2.5 SNPs/year) for L1 and 1.14x10-6 SNPs/site/year 115 
(approximately 3.4 SNPs/year) for L3. Based on these mutation rates and patient ward 116 
locations, we excluded direct patient-to-patient transmission of the CUH study isolates.  117 
We explored the genetic basis for the success of the dominant E. faecalis lineages 118 
using a candidate gene approach by comparing the prevalence of putative virulence and 119 
antibiotic resistance genes in L1, L2 and L3 isolates combined, versus the remainder. ace, 120 
gelE, asa1, agg, cyl, elrA, and genes conferring resistance to tetracyclines, aminoglycosides, 121 
trimethoprim, chloramphenicol, macrolides/lincosamides/streptogramin B (MLSB), 122 
quaternary ammonium compounds (qacs) and vancomycin were over-represented in L1-3 123 
compared to the rest (Fig. 3). There was a striking difference in the prevalence of genes 124 
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encoding aminoglycoside and vancomycin resistance, two commonly used antibiotics for 125 
enterococcal infection, in dominant versus non-dominant lineages. Our findings extend 126 
previous reports that epidemic lineages are enriched for multi-drug resistance and specific 127 
virulence determinants.6,7 We then compared the prevalence of the candidate virulence 128 
genes in VREfs versus VSEfs contained in L1, L2 and L3 (Supplementary Fig. 3). This showed no 129 
significant difference, indicating that over-representation of virulence genes is lineage- rather 130 
than VRE-specific.  131 
We then analysed the pangenome20 of the 168 isolates to obtain a more detailed 132 
understanding of their entire genomic repertoire. This indicated that E. faecalis has an open 133 
genome with a gamma value of 0.21 (Supplementary Fig. 4), corroborating results derived 134 
previously from the analysis of 5 genomes.21 The pangenome contained 8,202 genes, of 135 
which 1,967 genes were conserved across the collection. Of the 6,235 genes in the accessory 136 
genome, 1,687 were present just once. The most common accessory genes encoded 137 
hypothetical proteins (n=2,558), IS elements or transposons (n=177), phage or plasmid-138 
associated proteins (n=462 and n=113 respectively), transcriptional regulators (n=225), ABC 139 
transporters or cassettes (n=124), and phosphotransferase systems (n=118). A total of 819 140 
genes were only found in the three dominant lineages, of which 109 were present in more 141 
than 10 isolates (Supplementary Table 2), including a WxL domain surface protein unique to 142 
L1. Comparison of the amino acid sequence of the WxL protein from L1 to the proteome of 143 
V583 revealed a 100% match to EF_3248, one of 27 WxL proteins identified by Brinster et 144 
al.22 No genes or homoplasic non-synonymous SNPs were ubiquitous in the dominant 145 
lineages and absent from all sporadic lineages, suggesting that there is no single factor that 146 
contributed to the emergence of these dominant clones, although antibiotic resistance and 147 
virulence determinants are likely to represent multifactorial contributory factors. Analysis of 148 
non-synonymous SNPs unique to L3 revealed 122 SNPs in 95 genes (Supplementary Table 3), 149 
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but no single genetic event was identified that might explain the geographically constrained 150 
success of this lineage.  151 
Recombination is thought to be a major mechanism by which the E. faecalis genome 152 
evolves, which led us to estimate sites of recombination in the core genome23 for L1, L2 and 153 
L3 (Supplementary Fig. 5). Recombination accounted for 12.3% of the core genome in L1 154 
(6.5% related to a large recombination event in 2 isolates) and 3.9% in L2, with a single 155 
predicted 4 bp recombination event in one L3 isolate. This contrasts with reports that 156 
recombination across the species is high,4 which led us to use an alternative algorithm 157 
(BratNextGen24) to detect recombination. This revealed similarly low levels of recombination 158 
in L2 and L3 (6.2% and 0.3% respectively) but higher rates in L1 (37%), although most of this 159 
(93%) was contained within two large recombination events (Supplementary Fig. 5). One 160 
possible explanation for the low levels of recombination is that this drove the initial 161 
diversification of the species but subsequently contributed little to short-term evolution. 162 
Finally, we analysed the genetic basis of vancomycin resistance in the collection. 163 
Nearly all VREfs (57/58) carried vanA, with a single NCTC isolate carrying vanB. Annotation of 164 
the tree with resistance to vancomycin showed that all three dominant lineages contained a 165 
mixture of VREfs and VSEfs, with 89% of BSAC and 95% of CUH VREfs belonging to L1-3. Based 166 
on mapping to a reference vanA transposon (Tn1546) there was no SNP-based variation 167 
between transposons with the exception of one that had a C  T substitution at position 168 
5745. However, there was substantial variation in gene content. The transposase, resolvase, 169 
vanY and vanZ genes were not detected in some isolates, but despite this the minimum 170 
inhibitory concentration (available for the 35 vanA positive BSAC isolates) was consistently 171 
very high (≥256 mg/L). There was considerable variation in genetic content within and 172 
between the L1 and L2 transposon, whilst L3 had limited variation with two variants relating 173 
to VREfs isolated in 2006-2009 and 2009-2012 respectively, and three partial deletions (Fig. 174 
4). Analysis of the insertion sites for Tn1546 revealed multiple insertion sites for L1 and L2, 175 
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but only one site was identified for L3 in the 11/14 genomes for which this analysis proved 176 
possible (Fig. 4 and Supplementary Table 4). Analysis using BLAST revealed that these 177 
insertion sites were best matched to plasmids, a finding corroborated using plasmid 178 
extraction and vanA hybridization for insertion site types 1A, 1B, 2B and 3 (data not shown). 179 
These data indicate multiple acquisition and loss of the vanA transposon in L1 and L2, 180 
suggesting a significant fitness cost. By contrast, the single acquisition followed by clonal 181 
expansion in L3 suggests that the transposon has negligible cost or confers a benefit in this 182 
lineage. Foucault et al.25 demonstrated that its integration site in the chromosome 183 
predominantly determined the fitness cost of the vanB transposon. One possible reason for 184 
the retention of vanA in L3 is that the transposon has inserted into the plasmid at a location 185 
that lacks a fitness cost to the bacterium. However, vanA is inserted at the same site in 10 186 
isolates from L1 and L2 and there is limited evidence for retention of vanA in these isolates. 187 
 In conclusion, whole genome sequencing of E. faecalis has highlighted the dominance 188 
of epidemic lineages in the UK&I, but also showed that a lineage with features of an epidemic 189 
lineage was confined to two hospitals. Additionally, we identified that the UK and US have 190 
genetically distinct populations belonging to two of these lineages, suggesting a lack of 191 
international transmission. The mutation rate defined here will have utility in clinical practice 192 
as sequencing technology is introduced into the investigation of putative outbreaks. Genome-193 
level data provided comprehensive insights into the gene content of dominant versus 194 
sporadic lineages and allowed us to describe the evolution of vancomycin resistance in this 195 
collection, which included multiple loss and acquisition events. The observation that the 196 
major VREfs lineages were also the common lineages for VSEfs has important implications for 197 
infection control and antibiotic stewardship, since the control of VREfs is likely to depend on 198 
defining and addressing drivers for VSEfs and its transmission.  199 
 200 
 201 
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ONLINE METHODS 202 
Ethical approval 203 
The study was approved by the National Research Ethics Service (ref: 12/EE/0439) and the 204 
Cambridge University Hospitals NHS Foundation Trust (CUH) Research and Development 205 
(R&D) Department.  206 
 207 
Isolate collection 208 
The 168 Enterococcus faecalis isolates used in this study were selected from three 209 
collections: NCTC (n=14, deposited between 1927 and 2007), BSAC (n=94, isolated between 210 
2001 and 2011) and CUH (n=60, isolated between Nov 2006 and Dec 2012). The collection 211 
was enriched for vancomycin-resistant isolates by selecting all of the available VREfs from 212 
NCTC (n=3) and BSAC (n=35) and the first stored isolate from all cases of VREfs bacteremia at 213 
CUH (n=20). To relate this to the underlying VSEfs population, 110 VSEfs were selected as 214 
follows: (i) all available VSEfs from the NCTC (n=11), (ii) 59 VSEfs from BSAC (35 matched to 215 
the BSAC VREfs cases by hospital and year of isolation where available, and an additional 24 216 
VSEfs to gain greater representation of the VSEfs population); (iii) 40 VSEfs from CUH (the 217 
first stored bacteremia-associated isolate matched to CUH VREfs cases by isolation date 218 
(n=17), or that occurred 30 days or more after admission (n=19), and 4 additional VSEfs that 219 
were available to increase the representation of the local population). BSAC hospitals were 220 
assigned to referral networks described previously,12 which are clusters of hospitals more 221 
likely to exchange patients within the cluster than outside of that cluster. 222 
 223 
Microbiology and sequencing  224 
Bacterial isolates were cultured on Columbia Blood Agar (Oxoid, Basingstoke, UK) and 225 
incubated at 37°C for 48 hours in air. Vancomycin susceptibility was determined using the 226 
agar dilution method26 (BSAC isolates), or the Vitek2 instrument (Biomerieux, Marcy l’Etoile, 227 
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France) with the AST-P607 card (CUH and NCTC VREfs isolates). DNA was extracted using the 228 
QIAxtractor (QIAgen), according to the manufacturer’s instructions. Library preparation was 229 
conducted according to the Illumina protocol, and sequencing was performed on an Illumina 230 
HiSeq2000 with 100-cycle paired-end runs. Sequence data for all isolates have been 231 
submitted to the European Nucleotide Archive (ENA) (www.ebi.ac.uk/ena) with the accession 232 
numbers shown in Supplementary Table 1. 233 
 234 
Phylogenetic analyses 235 
Sequence reads were mapped using SMALT 236 
(http://www.sanger.ac.uk/resources/software/smalt/) to the E. faecalis reference genome 237 
V583 (ENA accession number AE016830) for collection-wide analysis. This reference was 238 
selected because it is one of only two finished E. faecalis genomes from clinical isolates, and 239 
has been used in multiple studies (the second complete genome having only been published 240 
in 2014). For analysis of lineages L1, L2 and L3, the oldest isolate from each lineage was 241 
selected as a reference for mapping and an assembly created using Velvet. Mobile genetic 242 
elements were identified using gene annotation, PHAST27 (phast.wishartlab.com), WebACT28 243 
(http://www.webact.org) and BLAST29 (blast.ncbi.nlm.nih.gov) and were excluded in addition 244 
to contigs less than 500bp in length to create a ‘core’ genome. The core genome sizes were 245 
2,886,189, 2,698,500bp, 2,372,434bp and 2,707,007bp for V583, L1, L2 and L3, respectively.  246 
Single nucleotide polymorphisms (SNPs) in the core genome were determined using an in-247 
house script and used to estimate maximum likelihood trees using RAxML30 with 100 248 
bootstraps. Recombination was removed from the lineage-specific analyses using Gubbins.23 249 
To place the isolates into a global context, all of the available E. faecalis sequences listed in 250 
GenBank were downloaded from the ENA (n=353). Six isolates were excluded due to poor 251 
assemblies/annotation. The assemblies of the remaining 347 isolates were combined with 252 
the assemblies of the study isolates (created using Velvet), annotated with Prokka, and a pan-253 
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genome estimated using Roary.20 A 90% identity cut-off was used and core genes were 254 
defined as those in 99% of isolates. A maximum likelihood tree of the 25,294 SNPs in the 255 
1,416 core genes was created using RAxML and 100 bootstraps. iTOL31 and FigTree were used 256 
to visualise the trees. Assemblies were compared to the MLST database 257 
(pubmlst.org/efaecalis/) sited at the University of Oxford32 using an in-house script.  258 
 259 
Population history and mutation rate 260 
Genetic diversity was calculated based on pairwise SNP differences. Bayesian Evolutionary 261 
Analysis Sampling Trees (BEAST)15 was used to date the phylogeny and estimate a mutation 262 
rate for L1 and L3 using the core genome after removal of regions of recombination using 263 
Gubbins. BratNextGen24 was used to verify the results of Gubbins for L1 using the following 264 
parameters: 10 iterations, 100 permutation runs and a significance threshold of 0.05.  One 265 
NCTC isolate was excluded from the analysis for L1 because the isolation date was unknown. 266 
A Hasegawa, Kishino and Yano (HKY) model and gamma distribution was used, and the best 267 
molecular clock and tree selected based on Bayes factors calculated from path sampling and 268 
stepping stone sampling33,34: for L3 an exponential clock and constant tree were used, for L1 a 269 
lognormal clock and Bayesian skyline tree were used, and for the repeat analysis of L1 (with 270 
recombination events identified and removed based on BratNextGen) a lognormal clock and 271 
constant tree were used.  272 
 273 
Detection of candidate genes 274 
Virulence genes were chosen based on evidence from experimental mammalian models35 and 275 
their presence determined by in silico PCR using previously published primers: ace,36 esp,37 276 
gelE,38 asa1,39 agg36 and cyl,40 elrA (OEF2 and OEF8) 41, gls24,42 tpx (ef1933for and tpxrev) 43, 277 
bgsA (bgsA for and bgsArev) 44, srtA (EF3056F and EF3056R) 45, sigV (SVRT1-2) 46, epaA 278 
(AB270_epa_F and AB271_epa_R)47, epaB (AB272_epaB_F and AB273_epaB_R) 47, epaE 279 
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(AB276_epaE_F and AB277_epaE_R) 47, epaN (AB288_epaN_F and AN289_epaN_R) 47 and 280 
perA (perA-FF and perA-RR) 48. The presence of msrA and msrB were determined by coverage 281 
of EF1681 and EF3164 respectively, when mapped to the V583 reference genome. The 282 
presence of vanA and vanB were established by in silico PCR using published primers.35,49 283 
Genes encoding resistance to additional antimicrobial drugs were detected by comparing the 284 
whole genome of each isolate with the ResFinder database (compiled in 2012), 50 which has 285 
been manually curated since publication. Sequences were compared using an in-house script, 286 
and genes with 100% match to length and > 90% identity match were classified as present. In 287 
silico PCR using previously published primers was used for genes not in the ResFinder 288 
database: dfrF51 and qacZ52. Statistical significance was determined using Fisher’s exact test.  289 
 290 
Pangenome and recombination 291 
The pan genome was estimated using Roary.20 Core genes were defined as those present in 292 
all 168 isolates with a 90% ID cut-off. The proteome of E. faecalis strain V583 was 293 
downloaded from the ENA and interrogated with the WxL protein described in this study 294 
using the protein version of BLAST. Recombination was identified within L1-L3 using Gubbins 295 
and verified using BratNextGen as described above. 296 
 297 
Characterising the Tn1546 transposon 298 
Sequence reads for each isolate were mapped to Tn1546 (accession number M97297) from 299 
the E. faecium strain BM4147 using SMALT. The depth of coverage was between ~30x and 300 
~500x for all isolates, with 53/57 (93%) at a depth of > ~50x. To identify the insertion sites, 301 
the sequences adjacent to the start and end of the Tn1546 transposons were extracted from 302 
the assemblies up to a maximum of 10,000bp or the end of the contig. The sequences 303 
adjacent to the start of Tn1546 were too short to analyse but sequences adjacent to the end 304 
of Tn1546 (termed “insertion site sequences”) were compared between isolates. Insertion 305 
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site sequences that were identical for more than 200bp were grouped (groups 1-3 in 306 
Supplementary Table 4), and then subgroups defined if there were any changes in the 307 
downstream sequence, with no evidence that an insertion or deletion explain this change 308 
(changes described in Supplementary Table 4). Where the insertion site sequence available 309 
was too short to determine which subgroup it belonged to, this was categorised into 310 
subgroup A (the most prevalent subgroup) for simplification of Fig. 4. Each subgroup was 311 
identified as plasmid or chromosome-based using BLAST, with transposons considered 312 
plasmid-borne if the highest match was to a plasmid and there was no match above 25% 313 
coverage to an E. faecalis chromosome. Insertion site sequences less than 250bp were not 314 
considered long enough for an accurate identification. To verify whether the vanA 315 
transposons were located on plasmids, plasmid extraction followed by vanA hybridization 316 
was performed.  Representative isolates were selected for each of the transposon insertion 317 
sites defined using the sequence data. Plasmids were extracted using the Kado and Liu53 318 
method except that 100 mg/ml lysozyme was added with the E buffer followed by incubation 319 
for 1 hour. Extracts were run on a 0.7% agarose gel and blotted using capillary transfer onto 320 
Hybond N+ (Amersham, Buckinghamshire, UK). Hybridization was performed using the DIG-321 
high prime labeling and detection starter kit I (Roche Applied Science, Mannheim, Germany), 322 
and luminescence was detected using CSPD (Roche Applied Science). E. faecium BM4147 and 323 
NCTC 8132 were used as positive and negative controls, respectively, and two isolates with 324 
known plasmid sizes were used as size markers (Yersinia enterolitica YE212/92 (BT 2, O:9) and 325 
YE53/03 (BT 1A, O:5)). Probes were created using the following primers: vanA-1: 5’-326 
GGGAAAACGACAATTGC-3’, vanA-2: 5’GTACAATGCGGCCGTTA-3’.49  327 
 328 
Accession codes 329 
The sequence data for the study isolates has been deposited in the ENA under the study 330 
accessions PRJEB4344, PRJEB4345 and PRJEB4346, with the accession numbers for individual 331 
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isolates listed in Supplementary Table 1. Additional sequences used in this study were the E. 332 
faecalis reference genome V583 (ENA accession number AE016830) and Tn1546 from the E. 333 
faecium strain BM4147 (ENA accession number M97297).  334 
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Figure legends 427 
Figure 1. Phylogeny of E. faecalis isolates drawn from across the United Kingdom and 428 
Ireland. Left hand side: Midpoint rooted maximum likelihood tree of 168 E. faecalis isolates 429 
based on SNPs in the core genome.  Colored branches indicate the three dominant lineages 430 
(L1, red; L2, purple; L3, turquoise). The vertical bars show the source of each isolate (dark 431 
blue, BSAC; light blue, CUH; yellow, NCTC) and presence (red) or absence (blue) of 432 
vancomycin resistance determinants. Bootstrap supports over 90% are labelled for the major 433 
nodes. Scale bar indicates 10,000 SNPs. Right hand side: Maximum likelihood trees of the 434 
three dominant lineages based on SNPs in the core genome after recombination was 435 
removed, and rooted on an outlier. The trees are labelled by referral network, with ‘_1’ and 436 
‘_2’ indicating different hospitals within the referral network if more than one contributed to 437 
the BSAC study collection, and year of isolation with CUH isolates highlighted blue. Bootstrap 438 
supports over 90% are labelled. Scale bars indicate 25 SNPs.  439 
 440 
Figure 2: Global population structure of E. faecalis. Phylogeny of 168 study isolates 441 
combined with 347 isolates from geographically diverse locations downloaded from the 442 
European Nucleotide Archive (ENA). Maximum likelihood tree based on SNPs in the 1,293 443 
genes conserved in 99% of isolates. Colored branches indicate the three dominant lineages L1 444 
(red), L2 (purple) and L3 (turquoise). Inner colored ring indicates the country of isolation, 445 
outer colored ring indicates the source of the isolate.  446 
 447 
Figure 3: Prevalence of virulence and antibiotic resistance genes in the dominant lineages 448 
(L1-3, n=89) and remainder (n=79). Graphs show the percentage of isolates for which 449 
putative virulence genes (a) or antibiotic resistance genes (grouped by antibiotic class) (b) 450 
were detected.  Genes that were ubiquitous in the collection are not shown. p values are 451 
shown when a significant difference was observed using Fisher’s exact test. Virulence genes: 452 
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ace = collagen adhesion protein; agg= aggregation substance; asa1= aggregation substance; 453 
bgsA = biofilm-associated glycolipid synthesis A; cyl= cytolysin; elrA = enterococcal leucine-454 
rich protein A; esp= enterococcal surface protein; gelE = gelatinase ; perA = pathogenicity 455 
island-encoded regulator; tpx = thiol peroxidase. Antibiotic resistance genes: Am = 456 
aminoglycosides (comprising one or more of aac6’-2”, aph3”-III, aacA, ant-6-Ia, str); Chlor = 457 
chloramphenicol (cat); Linc = lincosamides (lnuB); MLSB = macrolide, lincosamide, 458 
streptogramin B (comprising ermB or ermT); Tet= tetracycline (comprising one or more of 459 
tetL, tetM, tetO, tetS); Trim = trimethoprim (comprising dfrC, dfrD, dfrF or dfrG); Qac = 460 
quaternary ammonium compounds and other antiseptics (qacZ), Vanc = vancomycin. 461 
 462 
Figure 4. Mapping variation in the vancomycin resistance transposon. Midpoint rooted 463 
maximum likelihood tree of all 168 E. faecalis with the 3 dominant lineages highlighted (L1, 464 
red; L2, purple; L3, turquoise) and the presence (red) or absence (blue) of a van transposon 465 
indicated in the vertical bar. The right hand side shows the coverage plot (number of 466 
sequence reads that map to that location) of the vanA transposon in each isolate, with black 467 
indicating presence (30x coverage or above), graduating to white indicating absence (less 468 
than 10x coverage). The genes are labelled in the top bar (tn = inverted repeat). Colors in the 469 
vertical bar on the right indicate the different insertion sites in the three dominant lineages, 470 
with a description of each color available in Supplementary Table 4. Scale bar indicates 471 
10,000 SNPs. 472 
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